{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T14:28:57Z","timestamp":1794580137268,"version":"4.9.1"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T00:00:00Z","timestamp":1706832000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T00:00:00Z","timestamp":1706832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Multiple myeloma is a genetically complex and heterogenous malignancy with a 5-year survival rate of approximately 60%. Despite advances in therapy, patients experience cycles of remission and relapse, with each successive line of therapy associated with poorer outcomes; therefore, therapies with different mechanisms of action against new myeloma antigens are needed. G protein\u2013coupled receptor class C group 5 member D (GPRC5D) has emerged as a novel therapeutic target for the treatment of multiple myeloma. We review the biology and target validation of GPRC5D, and clinical data from early phase trials of GPRC5D-targeting bispecific antibodies, talquetamab and forimtamig, and chimeric antigen receptor T cell (CAR-T) therapies, MCARH109, OriCAR-017, and BMS-986393. In addition to adverse events (AEs) associated with T-cell\u2013redirection therapies irrespective of target, a consistent pattern of dermatologic and oral AEs has been reported across several trials of GPRC5D-targeting bispecific antibodies, as well as rare cerebellar events with CAR-T therapy. Additional studies are needed to understand the underlying mechanisms involved in the development of skin- and oral-related toxicities. We review the strategies that have been used to manage these GPRC5D-related toxicities. Preliminary efficacy data showed overall response rates for GPRC5D-targeting T-cell\u2013redirecting therapies were \u226564%; most responders achieved a very good partial response or better. Pharmacokinetics\/pharmacodynamics showed that these therapies led to cytokine release and T-cell activation. In conclusion, results from early phase trials of GPRC5D-targeting T-cell\u2013redirecting agents have shown promising efficacy and manageable safety profiles, including lower infection rates compared with B-cell maturation antigen- and Fc receptor-like protein 5-targeting bispecific antibodies. Further clinical trials, including those investigating GPRC5D-targeting T-cell\u2013redirecting agents in combination with other anti-myeloma therapies and with different treatment modalities, may help to elucidate the future optimal treatment regimen and sequence for patients with multiple myeloma and improve survival outcomes.<\/jats:p>","DOI":"10.1038\/s41408-023-00966-9","type":"journal-article","created":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T01:02:25Z","timestamp":1706835745000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":109,"title":["GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5236-7785","authenticated-orcid":false,"given":"Paula","family":"Rodriguez-Otero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels W. C. J.","family":"van de Donk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kodandaram","family":"Pillarisetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Cornax","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deeksha","family":"Vishwamitra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandi","family":"Hilder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaszianne","family":"Tolbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Renaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Masterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Heuck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen","family":"Kane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raluca","family":"Verona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1780-8746","authenticated-orcid":false,"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7353-7034","authenticated-orcid":false,"given":"Nizar","family":"Bahlis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajai","family":"Chari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,2]]},"reference":[{"key":"966_CR1","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","volume":"4","author":"AJ Cowan","year":"2018","unstructured":"Cowan AJ, Allen C, Barac A, Basaleem H, Bensenor I, Curado MP, et al. Global burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016. JAMA Oncol. 2018;4:1221\u20137. https:\/\/doi.org\/10.1001\/jamaoncol.2018.2128","journal-title":"JAMA Oncol"},{"key":"966_CR2","doi-asserted-by":"publisher","first-page":"232546","DOI":"10.1155\/2014\/232546","volume":"2014","author":"S de Mel","year":"2014","unstructured":"de Mel S, Lim SH, Tung ML, Chng WJ. Implications of heterogeneity in multiple myeloma. Biomed Res Int. 2014;2014:232546 https:\/\/doi.org\/10.1155\/2014\/232546","journal-title":"Biomed Res Int"},{"key":"966_CR3","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","volume":"364","author":"A Palumbo","year":"2011","unstructured":"Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364:1046\u201360. https:\/\/doi.org\/10.1056\/NEJMra1011442","journal-title":"N Engl J Med"},{"key":"966_CR4","unstructured":"Cancer stat facts: myeloma. 2023. https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html."},{"key":"966_CR5","unstructured":"Globocan 2020 world fact sheet: world. 2020. https:\/\/gco.iarc.fr\/today\/data\/factsheets\/populations\/900-world-fact-sheets.pdf"},{"key":"966_CR6","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1007\/s12325-020-01546-0","volume":"38","author":"J He","year":"2021","unstructured":"He J, Schmerold L, Van Rampelbergh R, Qiu L, Potluri R, Dasgupta A, et al. Treatment pattern and outcomes in newly diagnosed multiple myeloma patients who did not receive autologous stem cell transplantation: a real-world observational study: treatment pattern and outcomes in patients with multiple myeloma. Adv Ther. 2021;38:640\u201359. https:\/\/doi.org\/10.1007\/s12325-020-01546-0","journal-title":"Adv Ther"},{"key":"966_CR7","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"Cowan AJ, Green DJ, Kwok M, Lee S, Coffey DG, Holmberg LA, et al. Diagnosis and management of multiple myeloma: a review. JAMA. 2022;327:464\u201377. https:\/\/doi.org\/10.1001\/jama.2022.0003","journal-title":"JAMA"},{"key":"966_CR8","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1200\/jco.2015.65.0044","volume":"34","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Sonneveld P, Leung N, Merlini G, Ludwig H, Kastritis E, et al. International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment. J Clin Oncol. 2016;34:1544\u201357. https:\/\/doi.org\/10.1200\/jco.2015.65.0044","journal-title":"J Clin Oncol"},{"key":"966_CR9","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s00520-020-05493-y","volume":"29","author":"M Kamal","year":"2021","unstructured":"Kamal M, Wang XS, Shi Q, Zyczynski TM, Davis C, Williams LA, et al. Symptom burden and its functional impact in patients with \u201csymptomatic\u201d relapsed or refractory multiple myeloma. Support Care Cancer. 2021;29:467\u201375. https:\/\/doi.org\/10.1007\/s00520-020-05493-y","journal-title":"Support Care Cancer"},{"key":"966_CR10","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1111\/ejh.12790","volume":"97","author":"C Ramsenthaler","year":"2016","unstructured":"Ramsenthaler C, Kane P, Gao W, Siegert RJ, Edmonds PM, Schey SA, et al. Prevalence of symptoms in patients with multiple myeloma: a systematic review and meta-analysis. Eur J Haematol. 2016;97:416\u201329. https:\/\/doi.org\/10.1111\/ejh.12790","journal-title":"Eur J Haematol"},{"key":"966_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2410-2","volume":"16","author":"C Ramsenthaler","year":"2016","unstructured":"Ramsenthaler C, Osborne TR, Gao W, Siegert RJ, Edmonds PM, Schey SA, et al. The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: a multi-centre study. BMC Cancer. 2016;16:427 https:\/\/doi.org\/10.1186\/s12885-016-2410-2","journal-title":"BMC Cancer"},{"key":"966_CR12","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1001\/archneur.61.9.1423","volume":"61","author":"KO Schluterman","year":"2004","unstructured":"Schluterman KO, Fassas AB, Van Hemert RL, Harik SI. Multiple myeloma invasion of the central nervous system. Arch Neurol. 2004;61:1423\u20139. https:\/\/doi.org\/10.1001\/archneur.61.9.1423","journal-title":"Arch Neurol"},{"key":"966_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-017-0037-4","volume":"8","author":"E Terpos","year":"2018","unstructured":"Terpos E, Ntanasis-Stathopoulos I, Gavriatopoulou M, Dimopoulos MA. Pathogenesis of bone disease in multiple myeloma: from bench to bedside. Blood Cancer J. 2018;8:7 https:\/\/doi.org\/10.1038\/s41408-017-0037-4","journal-title":"Blood Cancer J"},{"key":"966_CR14","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.6004\/jnccn.2020.7561","volume":"18","author":"AK Zaleta","year":"2020","unstructured":"Zaleta AK, Miller MF, Olson JS, Yuen EYN, LeBlanc TW, Cole CE, et al. Symptom burden, perceived control, and quality of life among patients living with multiple myeloma. J Natl Compr Canc Netw. 2020;18:1087\u201395. https:\/\/doi.org\/10.6004\/jnccn.2020.7561","journal-title":"J Natl Compr Canc Netw"},{"key":"966_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07503-y","volume":"20","author":"R Fonseca","year":"2020","unstructured":"Fonseca R, Usmani SZ, Mehra M, Slavcev M, He J, Cote S, et al. Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma. BMC Cancer. 2020;20:1087 https:\/\/doi.org\/10.1186\/s12885-020-07503-y","journal-title":"BMC Cancer"},{"key":"966_CR16","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s40265-022-01697-0","volume":"82","author":"B Paul","year":"2022","unstructured":"Paul B, Rodriguez C, Usmani SZ. BCMA-targeted biologic therapies: the next standard of care in multiple myeloma therapy. Drugs. 2022;82:613\u201331. https:\/\/doi.org\/10.1007\/s40265-022-01697-0","journal-title":"Drugs"},{"key":"966_CR17","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/ajh.25791","volume":"95","author":"SV Rajkumar","year":"2020","unstructured":"Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95:548\u201367. https:\/\/doi.org\/10.1002\/ajh.25791","journal-title":"Am J Hematol"},{"key":"966_CR18","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/s0167-4781(01)00197-x","volume":"1518","author":"H Br\u00e4uner-Osborne","year":"2001","unstructured":"Br\u00e4uner-Osborne H, Jensen AA, Sheppard PO, Brodin B, Krogsgaard-Larsen P, O\u2019Hara P. Cloning and characterization of a human orphan family C G-protein coupled receptor GPRC5D. Biochim Biophys Acta. 2001;1518:237\u201348. https:\/\/doi.org\/10.1016\/s0167-4781(01)00197-x","journal-title":"Biochim Biophys Acta"},{"key":"966_CR19","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1046\/j.0022-202X.2004.12628.x","volume":"122","author":"S Inoue","year":"2004","unstructured":"Inoue S, Nambu T, Shimomura T. The RAIG family member, GPRC5D, is associated with hard-keratinized structures. J Investig Dermatol. 2004;122:565\u201373. https:\/\/doi.org\/10.1046\/j.0022-202X.2004.12628.x","journal-title":"J Investig Dermatol"},{"key":"966_CR20","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1182\/blood.2019003342","volume":"135","author":"K Pillarisetti","year":"2020","unstructured":"Pillarisetti K, Edavettal S, Mendon\u00e7a M, Li Y, Tornetta M, Babich A, et al. A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma. Blood. 2020;135:1232\u201343. https:\/\/doi.org\/10.1182\/blood.2019003342","journal-title":"Blood"},{"key":"966_CR21","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1182\/bloodadvances.2020003805","volume":"5","author":"CPM Verkleij","year":"2021","unstructured":"Verkleij CPM, Broekmans MEC, van Duin M, Frerichs KA, Kuiper R, de Jonge AV, et al. Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. Blood Adv. 2021;5:2196\u2013215. https:\/\/doi.org\/10.1182\/bloodadvances.2020003805","journal-title":"Blood Adv"},{"key":"966_CR22","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.ccell.2017.02.001","volume":"31","author":"J Li","year":"2017","unstructured":"Li J, Stagg NJ, Johnston J, Harris MJ, Menzies SA, DiCara D, et al. Membrane-proximal epitope facilitates efficient T cell synapse formation by anti-FcRH5\/CD3 and is a requirement for myeloma cell killing. Cancer Cell. 2017;31:383\u201395. https:\/\/doi.org\/10.1016\/j.ccell.2017.02.001","journal-title":"Cancer Cell"},{"key":"966_CR23","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1038\/leu.2016.388","volume":"31","author":"S Hipp","year":"2017","unstructured":"Hipp S, Tai YT, Blanset D, Deegen P, Wahl J, Thomas O, et al. A novel BCMA\/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo. Leukemia. 2017;31:1743\u201351. https:\/\/doi.org\/10.1038\/leu.2016.388","journal-title":"Leukemia"},{"key":"966_CR24","doi-asserted-by":"crossref","unstructured":"Goldsmith RB, Cornax I, Ma JY, Yao X, Peng P, Carreira V. Normal human tissue expression of G protein\u2013coupled receptor class C group 5 member D (GPRC5D), a promising novel target for multiple myeloma, is restricted to plasma cells and hard keratinized tissues. Poster presented at IMW; September 8-11, 2021; Vienna, Austria.","DOI":"10.1016\/S2152-2650(21)02229-1"},{"key":"966_CR25","doi-asserted-by":"publisher","first-page":"eaau7746","DOI":"10.1126\/scitranslmed.aau7746","volume":"11","author":"EL Smith","year":"2019","unstructured":"Smith EL, Harrington K, Staehr M, Masakayan R, Jones J, Long TJ, et al. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci Transl Med. 2019;11:eaau7746 https:\/\/doi.org\/10.1126\/scitranslmed.aau7746","journal-title":"Sci Transl Med"},{"key":"966_CR26","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1158\/1535-7163.Mct-18-1216","volume":"18","author":"T Kodama","year":"2019","unstructured":"Kodama T, Kochi Y, Nakai W, Mizuno H, Baba T, Habu K, et al. Anti-GPRC5D\/CD3 bispecific T-cell-redirecting antibody for the treatment of multiple myeloma. Mol Cancer Ther. 2019;18:1555\u201364. https:\/\/doi.org\/10.1158\/1535-7163.Mct-18-1216","journal-title":"Mol Cancer Ther"},{"key":"966_CR27","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1111\/j.1365-2362.2012.02679.x","volume":"42","author":"J Atamaniuk","year":"2012","unstructured":"Atamaniuk J, Gleiss A, Porpaczy E, Kainz B, Grunt TW, Raderer M, et al. Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma. Eur J Clin Investig. 2012;42:953\u201360. https:\/\/doi.org\/10.1111\/j.1365-2362.2012.02679.x","journal-title":"Eur J Clin Investig"},{"key":"966_CR28","doi-asserted-by":"crossref","unstructured":"Hasselbalch Riley C, Hutchings M, Yoon S, Koh Y, Manier S, Facon T, et al. RG6234, a novel GPRC5D T-Cell engaging bispecific antibody, induces rapid responses in patients with relapsed\/refractory multiple myeloma: preliminary results from a first-in-human trial. Oral presentation at EHA; June 9\u201312, 2022; Vienna, Austria.","DOI":"10.1097\/01.HS9.0000843612.41180.42"},{"key":"966_CR29","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","volume":"387","author":"S Mailankody","year":"2022","unstructured":"Mailankody S, Devlin SM, Landa J, Nath K, Diamonte C, Carstens EJ, et al. GPRC5D-targeted CAR T cells for myeloma. N Engl J Med. 2022;387:1196\u2013206. https:\/\/doi.org\/10.1056\/NEJMoa2209900","journal-title":"N Engl J Med"},{"key":"966_CR30","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1182\/blood-2013-09-529800","volume":"123","author":"I Frigyesi","year":"2014","unstructured":"Frigyesi I, Adolfsson J, Ali M, Christophersen MK, Johnsson E, Turesson I, et al. Robust isolation of malignant plasma cells in multiple myeloma. Blood. 2014;123:1336\u201340. https:\/\/doi.org\/10.1182\/blood-2013-09-529800","journal-title":"Blood"},{"key":"966_CR31","doi-asserted-by":"crossref","unstructured":"Cohen YC, Morillo D, Gatt M, Sebag M, Kim K, Min CK, et al. First results from the RedirecTT-1 study with teclistamab + talquetamab simultaneously targeting BCMA and GPRC5D in patients with relapsed\/refractory multiple myeloma Oral presentation at ASCO; June 2\u20136, 2023; Chicago, IL.","DOI":"10.1016\/S2152-2650(23)00864-9"},{"key":"966_CR32","doi-asserted-by":"publisher","first-page":"3794","DOI":"10.1182\/bloodadvances.2021004418","volume":"5","author":"MS Truger","year":"2021","unstructured":"Truger MS, Duell J, Zhou X, Heimeshoff L, Ruckdeschel A, John M, et al. Single- and double-hit events in genes encoding immune targets before and after T cell-engaging antibody therapy in MM. Blood Adv. 2021;5:3794\u20138. https:\/\/doi.org\/10.1182\/bloodadvances.2021004418","journal-title":"Blood Adv"},{"key":"966_CR33","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","volume":"29","author":"H Lee","year":"2023","unstructured":"Lee H, Ahn S, Maity R, Leblay N, Ziccheddu B, Truger M, et al. Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. Nat Med. 2023;29:2295\u2013306. https:\/\/doi.org\/10.1038\/s41591-023-02491-5","journal-title":"Nat Med"},{"key":"966_CR34","doi-asserted-by":"publisher","unstructured":"Derrien J, Gastineau S, Frigout A, Giordano N, Cherkaoui M, Gaborit V, et al. Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation. Nat Cancer. Published online September 1, 2023. https:\/\/doi.org\/10.1038\/s43018-023-00625-9.","DOI":"10.1038\/s43018-023-00625-9"},{"key":"966_CR35","doi-asserted-by":"publisher","first-page":"195","DOI":"10.2147\/dddt.S151282","volume":"12","author":"SE Sedykh","year":"2018","unstructured":"Sedykh SE, Prinz VV, Buneva VN, Nevinsky GA. Bispecific antibodies: design, therapy, perspectives. Drug Des Devel Ther. 2018;12:195\u2013208. https:\/\/doi.org\/10.2147\/dddt.S151282","journal-title":"Drug Des Devel Ther"},{"key":"966_CR36","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3390\/antib8030041","volume":"8","author":"WR Strohl","year":"2019","unstructured":"Strohl WR, Naso M. Bispecific T-cell redirection versus chimeric antigen receptor (CAR)-T cells as approaches to kill cancer cells. Antibodies. 2019;8:41 https:\/\/doi.org\/10.3390\/antib8030041","journal-title":"Antibodies"},{"key":"966_CR37","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","volume":"34","author":"N Shah","year":"2020","unstructured":"Shah N, Chari A, Scott E, Mezzi K, Usmani SZ. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia. 2020;34:985\u20131005. https:\/\/doi.org\/10.1038\/s41375-020-0734-z","journal-title":"Leukemia"},{"key":"966_CR38","doi-asserted-by":"publisher","first-page":"762","DOI":"10.3389\/fimmu.2020.00762","volume":"11","author":"M Lejeune","year":"2020","unstructured":"Lejeune M, K\u00f6se MC, Duray E, Einsele H, Beguin Y, Caers J. Bispecific, T-cell-recruiting antibodies in B-cell malignancies. Front Immunol. 2020;11:762 https:\/\/doi.org\/10.3389\/fimmu.2020.00762","journal-title":"Front Immunol"},{"key":"966_CR39","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3390\/antib8030043","volume":"8","author":"Q Wang","year":"2019","unstructured":"Wang Q, Chen Y, Park J, Liu X, Hu Y, Wang T, et al. Design and production of bispecific antibodies. Antibodies. 2019;8:43 https:\/\/doi.org\/10.3390\/antib8030043","journal-title":"Antibodies"},{"key":"966_CR40","doi-asserted-by":"publisher","first-page":"102625","DOI":"10.1016\/j.ebiom.2019.102625","volume":"52","author":"PJ Engelberts","year":"2020","unstructured":"Engelberts PJ, Hiemstra IH, de Jong B, Schuurhuis DH, Meesters J, Beltran Hernandez I, et al. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. EBioMedicine. 2020;52:102625 https:\/\/doi.org\/10.1016\/j.ebiom.2019.102625","journal-title":"EBioMedicine"},{"key":"966_CR41","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"A Chari","year":"2022","unstructured":"Chari A, Minnema MC, Berdeja JG, Oriol A, van de Donk N, Rodr\u00edguez-Otero P, et al. Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med. 2022;387:2232\u201344. https:\/\/doi.org\/10.1056\/NEJMoa2204591","journal-title":"N Engl J Med"},{"key":"966_CR42","unstructured":"Chari A, Touzeau C, Schinke C, Minnema MC, Berdeja JG, Oriol A, et al. Talquetamab, a G protein-coupled receptor family C group 5 member D \u00d7 CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma: phase 1\/2 results from MonumenTAL-1. Oral presentation at ASH; December 10-13, 2022; New Orleans, LA."},{"key":"966_CR43","unstructured":"U.S. Food and Drug Administration. TALVEY\u2122 (talquetamab-tgvs) prescribing information. 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761342s000lbl.pdf."},{"key":"966_CR44","unstructured":"European Medicines Agency. Summary of opinion on Talvey (talquetamab). 2023. https:\/\/www.ema.europa.eu\/en\/documents\/smop-initial\/chmp-summary-positive-opinion-talvey_en.pdf."},{"key":"966_CR45","doi-asserted-by":"crossref","unstructured":"Carlo-Stella C, Mazza R, Manier S, Facon T, Yoon S, Koh Y, et al. Forimtamig (RG6234), a GPRC5DxCD3 T cell engaging bispecific antibody, is highly active in patients with relapsed\/refractory multiple myeloma: updated intravenous and first subcutaneous results from a Phase I dose escalation study. Oral presentation at ASH; December 10\u201313, 2022; New Orleans, LA.","DOI":"10.1182\/blood-2022-157988"},{"key":"966_CR46","doi-asserted-by":"publisher","first-page":"4785","DOI":"10.1158\/1078-0432.Ccr-18-0455","volume":"24","author":"M Bacac","year":"2018","unstructured":"Bacac M, Colombetti S, Herter S, Sam J, Perro M, Chen S, et al. CD20-TCB with obinutuzumab pretreatment as next-generation treatment of hematologic malignancies. Clin Cancer Res. 2018;24:4785\u201397. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-18-0455","journal-title":"Clin Cancer Res"},{"key":"966_CR47","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1182\/blood-2022-157485","volume":"140","author":"J Eckmann","year":"2022","unstructured":"Eckmann J, Fauti T, Zabaleta A, Blanco L, Kassem S, Carri\u00e9 N, et al. RG6234: a novel 2:1 GPRC5D T cell bispecific antibody exhibits best in class potential for the treatment of multiple myeloma as a monotherapy and in combination. Blood. 2022;140:2091\u20132. https:\/\/doi.org\/10.1182\/blood-2022-157485","journal-title":"Blood"},{"key":"966_CR48","doi-asserted-by":"publisher","first-page":"215949","DOI":"10.1016\/j.canlet.2022.215949","volume":"553","author":"J Yang","year":"2023","unstructured":"Yang J, Zhou W, Li D, Niu T, Wang W. BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma. Cancer Lett. 2023;553:215949 https:\/\/doi.org\/10.1016\/j.canlet.2022.215949","journal-title":"Cancer Lett"},{"key":"966_CR49","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/s0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021;398:314\u201324. https:\/\/doi.org\/10.1016\/s0140-6736(21)00933-8","journal-title":"Lancet"},{"key":"966_CR50","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD Jr., Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384:705\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2024850","journal-title":"N Engl J Med"},{"key":"966_CR51","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","volume":"21","author":"RC Larson","year":"2021","unstructured":"Larson RC, Maus MV. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat Rev Cancer. 2021;21:145\u201361. https:\/\/doi.org\/10.1038\/s41568-020-00323-z","journal-title":"Nat Rev Cancer"},{"key":"966_CR52","doi-asserted-by":"publisher","first-page":"e107","DOI":"10.1016\/s2352-3026(22)00372-6","volume":"10","author":"M Zhang","year":"2023","unstructured":"Zhang M, Wei G, Zhou L, Zhou J, Chen S, Zhang W, et al. GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial. Lancet Haematol. 2023;10:e107\u2013e116. https:\/\/doi.org\/10.1016\/s2352-3026(22)00372-6","journal-title":"Lancet Haematol"},{"key":"966_CR53","unstructured":"Oricell website. 2022. https:\/\/www.oricell.com\/en\/about\/news\/143.html."},{"key":"966_CR54","doi-asserted-by":"crossref","unstructured":"Bal S, Kocoglu MH, Nadeem O, Htut M, Gregory T, Anderson LD, Jr., et al. Clinical activity of BMS-986393 (CC-95266), a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted chimeric antigen receptor (CAR) T cell therapy, in patients with relapsed and\/or refractory (R\/R) multiple myeloma (MM): first results from a phase 1, multicenter, open-label study. Oral presentation at ASH; December 10\u201313, 2022; New Orleans, LA.","DOI":"10.1182\/blood-2022-162395"},{"key":"966_CR55","doi-asserted-by":"crossref","unstructured":"van de Donk NW, Bahlis N, Mateos M, Weisel K, Dholaria B, Garfall AL, et al. Novel combination immunotherapy for the treatment of relapsed\/refractory multiple myeloma: updated phase 1b results for talquetamab (a GPRC5D x CD3 bispecific antibody) in combination with daratumumab. Oral presentation at EHA; June 9\u201312, 2022; Vienna, Austria.","DOI":"10.1097\/01.HS9.0000843624.82943.92"},{"key":"966_CR56","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1096\/fj.201700610RR","volume":"32","author":"P Rajkumar","year":"2018","unstructured":"Rajkumar P, Cha B, Yin J, Arend LJ, P\u0103unescu TG, Hirabayashi Y, et al. Identifying the localization and exploring a functional role for GPRC5C in the kidney. FASEB J. 2018;32:2046\u201359. https:\/\/doi.org\/10.1096\/fj.201700610RR","journal-title":"FASEB J"},{"key":"966_CR57","unstructured":"Touzeau C, Chari A, Schinke C, Minnema MC, Berdeja JG, Oriol A, et al. Health-related quality of life in patients with relapsed\/refractory multiple myeloma treated with talquetamab, a G protein-coupled receptor family C group 5 member D x CD3 bispecific antibody: patient-reported outcomes from MonumenTAL-1. Oral presentation at ASH; December 10\u201313, 2022; New Orleans, LA."},{"key":"966_CR58","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk N, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387:495\u2013505. https:\/\/doi.org\/10.1056\/NEJMoa2203478","journal-title":"N Engl J Med"},{"key":"966_CR59","unstructured":"Rodr\u00edguez-Otero P, Schinke C, Chari A, Lipe B, Lavi N, Rasche R, et al. Analysis of infections and parameters of humoral immunity in patients with relapsed\/refractory multiple myeloma treated with talquetamab monotherapy in MonumenTAL-1. Poster presented at ASCO; June 2\u20136, 2023; Chicago, IL."},{"key":"966_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00808-8","volume":"13","author":"BZ Sim","year":"2023","unstructured":"Sim BZ, Longhitano A, Er J, Harrison SJ, Slavin MA, Teh BW. Infectious complications of bispecific antibody therapy in patients with multiple myeloma. Blood Cancer J. 2023;13:34 https:\/\/doi.org\/10.1038\/s41408-023-00808-8","journal-title":"Blood Cancer J"},{"key":"966_CR61","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/s0140-6736(21)01338-6","volume":"398","author":"SZ Usmani","year":"2021","unstructured":"Usmani SZ, Garfall AL, van de Donk N, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab, a B-cell maturation antigen \u00d7 CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet. 2021;398:665\u201374. https:\/\/doi.org\/10.1016\/s0140-6736(21)01338-6","journal-title":"Lancet"},{"key":"966_CR62","doi-asserted-by":"crossref","unstructured":"Dekhtiarenko I, Lelios I, Attig J, Sleiman N, Lazzaro D, Clausen I, et al. T-cell activation and myeloma cell killing confirm the mode of action of RG6234, a novel GPRC5D T-cell engaging bispecific antibody, in patients with relapsed\/refractory multiple myeloma. Oral presentation at EHA; June 9\u201312, 2022; Vienna, Austria.","DOI":"10.1097\/01.HS9.0000843584.56113.c6"},{"key":"966_CR63","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s40259-018-0295-0","volume":"32","author":"B Bittner","year":"2018","unstructured":"Bittner B, Richter W, Schmidt J. Subcutaneous administration of biotherapeutics: an overview of current challenges and opportunities. BioDrugs. 2018;32:425\u201340. https:\/\/doi.org\/10.1007\/s40259-018-0295-0","journal-title":"BioDrugs"},{"key":"966_CR64","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.addr.2020.05.009","volume":"167","author":"M S\u00e1nchez-F\u00e9lix","year":"2020","unstructured":"S\u00e1nchez-F\u00e9lix M, Burke M, Chen HH, Patterson C, Mittal S. Predicting bioavailability of monoclonal antibodies after subcutaneous administration: Open innovation challenge. Adv Drug Deliv Rev. 2020;167:66\u201377. https:\/\/doi.org\/10.1016\/j.addr.2020.05.009","journal-title":"Adv Drug Deliv Rev"},{"key":"966_CR65","doi-asserted-by":"publisher","first-page":"6136","DOI":"10.3390\/cancers13236136","volume":"13","author":"SF Cho","year":"2021","unstructured":"Cho SF, Xing L, Anderson KC, Tai YT. Promising antigens for the new frontier of targeted immunotherapy in multiple myeloma. Cancers. 2021;13:6136 https:\/\/doi.org\/10.3390\/cancers13236136","journal-title":"Cancers"},{"key":"966_CR66","doi-asserted-by":"publisher","first-page":"11526","DOI":"10.3390\/ijms231911526","volume":"23","author":"A Nogami","year":"2022","unstructured":"Nogami A, Sasaki K. Therapeutic advances in immunotherapies for hematological malignancies. Int J Mol Sci. 2022;23:11526 https:\/\/doi.org\/10.3390\/ijms231911526","journal-title":"Int J Mol Sci"},{"key":"966_CR67","doi-asserted-by":"crossref","unstructured":"Sasaki M, Suzuki K, Abe Y, Ito S, Nishiwaki K, Handa H, et al. Efficacy and safety of ixazomib plus lenalidomide and dexamethasone following injectable proteasome inhibitor-based therapy in patients with relapsed\/refractory multiple myeloma. Poster presented at IMS; August 25\u201327, 2022; Los Angeles, CA.","DOI":"10.1097\/01.HS9.0000850908.45753.c0"},{"key":"966_CR68","doi-asserted-by":"publisher","first-page":"6020","DOI":"10.1158\/1538-7445.Am2022-6020","volume":"82","author":"W Huang","year":"2022","unstructured":"Huang W, Luo J, Li Y, Fei D, Qin X, Li R. Abstract 6020: Preclinical activity of LM-305 targeting G-protein-coupled receptor class 5 member D (GPRC5D) antibody drug conjugate for the treatment of multiple myeloma. Cancer Res. 2022;82:6020 https:\/\/doi.org\/10.1158\/1538-7445.Am2022-6020","journal-title":"Cancer Res"},{"key":"966_CR69","doi-asserted-by":"crossref","unstructured":"Dholaria B, Weisel K, Mateos MV, Goldschmidt H, Martin TG, Morillo D, et al. Talquetamab + daratumumab in patients with relapsed\/refractory multiple myeloma: updated TRIMM-2 results. Oral presentation at ASCO; June 2\u20136, 2023; Chicago, IL.","DOI":"10.1016\/S2152-2650(23)00805-4"}],"updated-by":[{"DOI":"10.1038\/s41408-024-01018-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T00:00:00Z","timestamp":1709683200000}}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00966-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00966-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00966-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T02:02:49Z","timestamp":1709776969000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00966-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,2]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["966"],"URL":"https:\/\/doi.org\/10.1038\/s41408-023-00966-9","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,2]]},"assertion":[{"value":"2 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2024","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41408-024-01018-6","URL":"https:\/\/doi.org\/10.1038\/s41408-024-01018-6","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"PRO reports a consulting or advisory role with AbbVie, BMS, GlaxoSmithKline, Janssen, Pfizer, and Sanofi; is on the speakers\u2019 bureau for BMS, GlaxoSmithKline, Janssen, and Sanofi; has received travel, accommodations, and expenses from Pfizer; and has received honoraria from AbbVie, Celgene, GlaxoSmithKline, H3 Biomedicine, Janssen, Pfizer, and Sanofi. NWCJvdD has received research funding from Amgen, BMS, Celgene, Cellectis, Janssen, and Novartis; and reports a consulting or advisory role with AbbVie, Adaptive Biotechnologies, Amgen, Bayer, BMS, Celgene, Janssen, Novartis, Pfizer, Roche, Servier, and Takeda. KP is an employee of Janssen Oncology and report stock and other ownership interests in Johnson & Johnson\/Janssen. IC is an employee of Janssen Oncology and reports stock and other ownership interests in Johnson & Johnson\/Janssen. DV is an employee of Janssen Oncology and reports stock and other ownership interests in Johnson & Johnson\/Janssen. KG is an employee of Janssen Oncology and reports stock and other ownership interests in Johnson & Johnson\/Janssen. BH is an employee of Janssen Oncology and reports stock and other ownership interests in Johnson & Johnson\/Janssen. JT is an employee of Johnson & Johnson and reports stock and other ownership in Johnson & Johnson; and has received research funding from Janssen Research & Development. TR is an employee of Janssen Oncology and reports stock and other ownership interests in Johnson & Johnson\/Janssen. TM is an employee of Janssen Research & Development and reports stock and other ownership interests in Johnson & Johnson. CH is an employee of Janssen Research & Development; reports stock and other ownership interests in Janssen Research & Development; and reports patents, royalties, and other intellectual property in Janssen Research & Development. CK is an employee of Janssen Research & Development; reports stock and other ownership interests in Janssen Research & Development; and has received travel, accommodation, and expenses from Janssen Research & Development. PM has served in a consulting\/advisory role and has received honoraria from AbbVie, Amgen, Celgene, GlaxoSmithKline, Janssen, Oncopeptides, and Sanofi. NB has served in a consulting\/advisory role for AbbVie, Amgen, Bristol Myers Squibb, Forus, Genentech, GlaxoSmithKline, Janssen, Pfizer, Sanofi, and Takeda; has received honoraria from AbbVie, Amgen, Bristol Myers Squibb, Forus, Janssen, Pfizer, and Sanofi; has received research funding from Pfizer; and has served as a member of an IRC and\/or steering committee for AbbVie, GlaxoSmithKline, and Janssen. AC reports a consulting or advisory role for AbbVie, Antengene, BMS, Genentech, Genzyme, GlaxoSmithKline, Janssen Oncology, Karyopharm Therapeutics, OncoPeptides, Seagen, Secura Bio, Shattuck Bio, Shattuck Labs, and Takeda; and has received research funding from Amgen, Celgene, Janssen, Pharmacyclics, Seagen, and Takeda.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24"}}